Nkarta, Inc. (NKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.92+4.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NKTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NKTX — earnings miss
Dated 2026-08-10
of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the “Securities Act”), unless the Company specifically states that the information is to be considered “filed” under the Exchange Act…
Why it matters: IRB approvals will allow more patients to access NKX019. This could expand the market and improve patient outcomes.
Supportive ifAll needed IRB approvals are in place for outpatient dosing at many sites.
Worry ifThere are delays or failures in getting IRB approvals for outpatient dosing.
Why it matters: R&D and G&A expenses directly affect net loss. Rising costs could indicate management struggles to control expenses.
Worry ifR&D and G&A expenses remain stable or decrease in the next quarter.
Less concerning ifR&D and G&A costs rise a lot beyond current levels.
Why it matters: Another earnings miss would confirm a trend of poor performance and could lead to negative sentiment.
Worry ifQ2 earnings are lower than what analysts expected.
Less concerning ifQ2 earnings are as good as or better than what analysts expected.
Why it matters: Losing more money may show worse financial health. This can hurt investor trust.
Worry ifOperating losses decrease from $30.9 million in Q1 2026.
Less concerning ifOperating losses increase beyond $30.9 million in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$303 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $736 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,305 loss on $10,000 · 43.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Successful implementation can improve patient access and enrollment in trials. This is key for Nkarta's growth.
Supportive ifOutpatient dosing is fully used at many sites.
Worry ifThere are delays or problems with outpatient dosing.
Why it matters: Initial data will show how effective NKX019 is for autoimmune diseases. This could impact future trials and investor confidence.
Supportive ifNtrust-1 and Ntrust-2 shared early clinical data at a medical conference in 2026.
Worry ifNo data was shared as planned, or data shows weak results.
Why it matters: FDA updates could impact patient enrollment and trial progress. Successful outpatient dosing is key for patient access.
Supportive ifThe FDA says it will keep approving outpatient dosing. This will happen in community settings.
Worry ifFDA cancels or delays approval for outpatient dosing.
Why it matters: Higher R&D costs could mean poor cost management. This may hurt the company's financial health.
Worry ifR&D costs are at or below $30 million. This shows good cost control.
Less concerning ifR&D costs go over $30 million. This raises worries about financial discipline.
Why it matters: Cash balance affects Nkarta's ability to keep running. A big drop could mean trouble.
Worry ifCash balance reported below $243.2 million in the next quarter.
Less concerning ifThe cash balance is over $243.2 million. This shows better cash management.
Why it matters: Higher losses could mean worse financial health and affect future funding.
Worry ifQ2 losses are reported over $30 million.
Less concerning ifQ2 losses are reported under $30 million.
Why it matters: A slowdown in sector growth could affect Nkarta's performance and how investors feel.
Worry ifSector revenue growth is below its median. This signals possible challenges.
Less concerning ifSector revenue growth is above median. This indicates continued strength.
Why it matters: If it drops below this level, it could worry investors about Nkarta's funding until 2029.
Worry ifCash balance is over $240 million. This shows good cash management.
Less concerning ifCash balance is below $240 million. This suggests possible funding problems.
Why it matters: If revenue growth picks up, it could signal a positive shift in performance. This would be important as the healthcare sector is slowing down.
Supportive ifNkarta reports revenue growth above 10% year over year in the next quarter.
Worry ifRevenue growth remains below 5% year over year in the next quarter.
Why it matters: This offering could impact share dilution and funding for operations. Investors will watch closely.
Watch forNkarta sells a lot of shares from the $100M offering.
Also watch forNkarta will stop or cut back the share offering.
Why it matters: Ongoing enrollment indicates strong interest and potential success in the NKX019 program. It shows that Nkarta is meeting its clinical goals.
Supportive ifEnrollment is ongoing at the 4 billion cell dose level for all uses.
Worry ifEnrollment slows or halts in either trial, indicating possible issues with the trials.
Why it matters: Tracking losses and expenses helps check Nkarta's financial health. Rising losses may mean cost issues.
Worry ifOperating losses decrease or stay the same. This shows better expense management.
Less concerning ifOperating losses increase beyond current levels. This shows worse financial health.
Why it matters: Cash balance updates will show if Nkarta can pay for operations until 2029.
Watch forCash balance is over $240 million, which confirms funding until 2029.
Also watch forCash balance falls below $240 million, raising worries about funding.